title: Glucose intolerance in children with cystic fibrosis.
abstract: OBJECTIVE
  To evaluate the relations among glucose intolerance, genotype, and exocrine pancreatic status in patients with cystic fibrosis (CF).
  
  
  METHODS
  Data on 335 patients <18 years of age were from the Toronto CF database. A modified oral glucose tolerance test was given to 94 patients 10 to 18 years of age without recognized CF-related diabetes. CF transmembrane conductance regulator mutations and exocrine pancreatic status were determined for all patients.
  
  
  RESULTS
  CF-related diabetes was clinically recognized in 9 of 335 (2.7%) patients <18 years of age, all of whom were pancreatic insufficient, and 8 of 9 had severe (classes I through III) mutations on both alleles. The ninth patient had unidentified mutations. Although all patients given the oral glucose tolerance test were asymptomatic and had normal fasting blood glucose, 16 of 94 (17%) had impaired glucose tolerance and 4 of 94 (4.3%) had CF-related diabetes without fasting hyperglycemia. Abnormal glucose tolerance was associated exclusively with severe mutations and exocrine pancreatic insufficiency. Glycosylated hemoglobin (HbA(1)C) levels did not correlate with glucose tolerance results.
  
  
  CONCLUSIONS
  Screening of pancreatic-insufficient, adolescent patients with CF identified more with abnormal oral glucose tolerance than was suspected clinically and is recommended as a routine practice. HbA(1)C was not useful in screening for CF-related glucose intolerance.
authors.affiliation: Departments of Genetics and Population Health Sciences, The Hospital for Sick Children, University of Toronto, Ontario, Canada.
authors.forename: Melinda P
authors.initials: MP
authors.lastname: Solomon
authors.forename: David C
authors.initials: DC
authors.lastname: Wilson
authors.forename: Mary
authors.initials: M
authors.lastname: Corey
authors.forename: Daina
authors.initials: D
authors.lastname: Kalnins
authors.forename: Julian
authors.initials: J
authors.lastname: Zielenski
authors.forename: Lap-Chee
authors.initials: LC
authors.lastname: Tsui
authors.forename: Paul
authors.initials: P
authors.lastname: Pencharz
authors.forename: Peter
authors.initials: P
authors.lastname: Durie
authors.forename: Neil B
authors.initials: NB
authors.lastname: Sweezey
mesh_terms: D000293:Adolescent; D001786:Blood Glucose / Q000032:analysis; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000235:genetics; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D003920:Diabetes Mellitus / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D005215:Fasting; D005260:Female; D005838:Genotype; D018149:Glucose Intolerance / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000378:metabolism; D006776:Hospitals, Pediatric; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods; D009154:Mutation / Q000235:genetics; D009864:Ontario / Q000453:epidemiology; D015995:Prevalence; D011446:Prospective Studies; D012189:Retrospective Studies
chemical_list: D001786:Blood Glucose; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D006442:Glycated Hemoglobin; C505032:CFTR protein, human